<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081558</url>
  </required_header>
  <id_info>
    <org_study_id>OuluUH2</org_study_id>
    <nct_id>NCT04081558</nct_id>
  </id_info>
  <brief_title>Electronic Symptom Follow-up of Cancer Patients</brief_title>
  <official_title>Follow-up of Cancer Patients Receiving Chemotherapy or Targeted Therapy by Electronic Patient Reported Outcomes-tool</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oulu University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of ePROs in oncological care have resulted in improvement of QoL, decreased ER visits,
      and improvement of overall survival. Furthermore, ePRO follow-up resulted in better QoL,
      improved ECOG status and more active cancer treatments at disease relapse, and improved
      survival among cancer survivals. The current study investigates electronic patient reported
      outcome tool in the follow-up of cancer patients receiving chemotherapies or targeted
      therapies.

      The aims of the current study are: 1) The number of alerts triggered by Kaiku Cancer medical
      treatment side-effects questionnaire and their correlation to treatment side-effects, other
      relevant medical events, tumor progression, and survival 2) Changes in Kaiku QLQ-C30 QoL
      questionnaire and their correlation to cancer treatment response, side-effects, other
      relevant medical event or survival 3) Patient compliance to Kaiku ePRO surveillance during
      treatment period according to response rates of Patient experience survey, Kaiku Cancer
      medical treatment side-effects questionnaire and Kaiku QLQ-C30 QoL questionnaire

      In addition, in the CRC (colorectal cancer) cohort:

        1. Integration of laboratory values to patient reported symptoms when prescribing a new
           chemotherapy cycle

        2. Number of phone calls related to prescribing a new chemotherapy cycle

        3. Unscheduled doctor appointments in oncology unit

        4. ER visits

        5. Days in hospitalization

        6. Unscheduled investigations in health care

        7. Development of peripheral neurotoxicity

        8. The number of chemotherapy dose reductions

        9. The number of chemotherapy delays

       10. Health care user experience survey
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the spectrum of patient reported symptoms</measure>
    <time_frame>At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks</time_frame>
    <description>Percentages of patient reported symptoms using KaikuHealth 15 symptom e-questionnaire. Individual questions evaluate the presence of a specific symptom e.g. nausea. Questions are answered yes or no.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Patient reported symptom severity</measure>
    <time_frame>At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks</time_frame>
    <description>Percentages of patient reported symptoms and their severity according NCI-CTCAE by KaikuHealth algorithm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the number of triggered alerts by the tool</measure>
    <time_frame>At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks</time_frame>
    <description>Number of triggered alerts by the tool and their correlation to treatment side-effects, cancer progression, other medical events in percentages or survival.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Quality of Life according to QLQ-C30 Summary scores</measure>
    <time_frame>At baseline, and at 4, 8, and 12weeks</time_frame>
    <description>The correlation of the Summary score of QLQ-C30 to treatment side-effects, cancer progression, or other medical events or survival.
The Core Quality of life questionnaire (QLQ-C30) is a validated cancer health-related quality-of-life questionnaire that includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality of life and financial impact. Subjects respond on a four-point-scale from &quot;not at all&quot; to &quot;very much&quot; for most items. Raw scores are linearly converted to a 0-100 scale. For the functioning scales and global QoL higher scores indicate better functioning; for the symptom scales higher scores indicate higher symptom burden. The summary score of QLQ-C30 is calculated from the mean of 13 of 15 QLQ-C30 scales (the Global Quality of Life scale and the Financial Impact scale are not included).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between changes in different symptoms and their severity to treatment side-effects, cancer progression, other medical events, or survival</measure>
    <time_frame>At 2-3, 4-5, 6-7, 8-9, and 11-12weeks</time_frame>
    <description>Correlation between different patient reported symptoms and their severity to treatment side-effects, cancer progression or other medical events in percentages or survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Patient compliance Questionnaire</measure>
    <time_frame>At 4, 8, and 12weeks</time_frame>
    <description>Patient compliance using KaikuHealth e-questionnaire addressing usability (easiness to use from scale: very easy to very difficult; need of assistance to use the program: yes/no; how understandable are questions in symptom questionnaire from scale: totally agree to totally disagree) and user experience (use of the ePRO tool will better your cancer care: yes-no, do not know; use of the ePRO tool has been useful: yes-no-do not know; would you recommend the ePRO tool for cancer care: yes-no-do not know). Analysis is done on percentages of each answer choice at specific time point(s).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in patient compliance according to answering rate to symptom questionnaires</measure>
    <time_frame>At 4, 8, and 12weeks</time_frame>
    <description>Patient compliance using response rates (within one week) to symptom questionnaires in percentages from sent requests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in patient compliance according to answering rates to QLQ-C30 questionnaire</measure>
    <time_frame>At 4, 8, and 12weeks</time_frame>
    <description>Patient compliance using response rates to QLQ-C30 questionnaires (within one week) in percentages from sent requests. The QLQ-C30 questionnaire includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality of life and financial impact. Subjects respond on a four-point-scale from &quot;not at all&quot; to &quot;very much&quot; for most items. Raw scores are linearly converted to a 0-100 scale. For the functioning scales and global QoL higher scores indicate better functioning; for the symptom scales higher scores indicate higher symptom burden. The summary score of QLQ-C30 is calculated from the mean of 13 of 15 QLQ-C30 scales (the Global Quality of Life scale and the Financial Impact scale are not included).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Integration of laboratory values to patient reported symptoms when prescribing a new chemotherapy cycle in the CRC cohort</measure>
    <time_frame>At 2-3 weeks cycle upon chemotherapy dosing schema during the treatment phase of the trial</time_frame>
    <description>An integrated electronic follow-up tool combining patient reported outcomes and the results of the safety laboratory values taken before treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of phone calls related to prescribing a new chemotherapy cycle in the CRC cohort</measure>
    <time_frame>At 2-3 weeks cycle upon chemotherapy dosing schema during the treatment phase of the trial</time_frame>
    <description>Number of un-scheduled phone calls to patients from health care professionals before a new chemotherapy cycle</description>
  </other_outcome>
  <other_outcome>
    <measure>Unscheduled doctor appointments in oncology unit in the CRC cohort</measure>
    <time_frame>During the treatment phase of the trial or up tp 24 weeks</time_frame>
    <description>The number of unscheduled doctor appointments in oncology unit due to patient-related issues</description>
  </other_outcome>
  <other_outcome>
    <measure>Emergency Clinic visits in the CRC cohort</measure>
    <time_frame>During the treatment phase of the trial or up to 24 weeks</time_frame>
    <description>The number of Emergency Clinic visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Days in hospitalization in the CRC cohort</measure>
    <time_frame>During the treatment phase of the trial or up to 24 weeks</time_frame>
    <description>The number of days in hospitalization</description>
  </other_outcome>
  <other_outcome>
    <measure>Unscheduled investigations in health care in the CRC cohort</measure>
    <time_frame>During the treatment phase of the trial or up to 24 weeks</time_frame>
    <description>The number of unscheduled investigations in health care</description>
  </other_outcome>
  <other_outcome>
    <measure>Development of peripheral neurotoxicity in the CRC cohort</measure>
    <time_frame>At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12 weeks</time_frame>
    <description>The severity of peripheral neurotoxicity according to NCI-CTCAE By KaikuHealth algorithm</description>
  </other_outcome>
  <other_outcome>
    <measure>The number of chemotherapy dose reductions</measure>
    <time_frame>During the treatment phase of the trial or up to 24 weeks</time_frame>
    <description>The number of chemotherapy dose reductions due to patient-related issues</description>
  </other_outcome>
  <other_outcome>
    <measure>The number of chemotherapy delays</measure>
    <time_frame>During the treatment phase of the trial or up to 24 weeks</time_frame>
    <description>The number of chemotherapy delays due to patient-related issues</description>
  </other_outcome>
  <other_outcome>
    <measure>Health care user experience survey</measure>
    <time_frame>Monthly during the treatment phase of the trial or up to 24 weeks</time_frame>
    <description>A questionnaire assessing the feasibility of electronic follow-up from health care professionals point of view</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Electronic follow-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electronic patient reported outcomes tool</intervention_name>
    <description>Electronic patient reported outcomes</description>
    <arm_group_label>Electronic follow-up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent prior to any study procedure

          2. Advanced breast, lung, colorectal, or pancreatic cancer

          3. New cancer medical treatment, chemotherapy or targeted therapy initiated within -/+ 2
             weeks from signed consent

          4. Age â‰¥18y

          5. ECOG 0-2

          6. CRC cohort: Patients with adjuvant treatment, or first or second line of treatment for
             metastatic disease

          7. Patient compliant with study procedures

        Exclusion Criteria:

          1. Initiation of new cancer medical treatment &gt; 2 wks from signed consent

          2. Any medical condition that the Investigator considers significant to compromise the
             safety of the patient or that impairs the interpretation of study assessments

          3. No internet access/email
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jussi Koivunen</last_name>
    <phone>+358853789</phone>
    <email>jussi.koivunen@ppshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanna Iivanainen</last_name>
    <phone>+358853038</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanna Iivanainen</last_name>
      <phone>+358853038</phone>
      <email>sanna.iivanainen@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Jussi Koivunen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanna Iivanainen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vaasa Central Hospital</name>
      <address>
        <city>Vaasa</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antti Jekunen</last_name>
      <email>antti.jekunen@vshp.fi</email>
    </contact>
    <investigator>
      <last_name>Antti Jekunen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oulu University Hospital</investigator_affiliation>
    <investigator_full_name>Jussi Koivunen</investigator_full_name>
    <investigator_title>adjuvant professor, medical oncologist</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04081558/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

